kabutan

HEALIOS K.K.(4593) Summary

4593
TSE Growth
HEALIOS K.K.
688
JPY
+10
(+1.47%)
Jul 28, 12:38 pm JST
4.67
USD
Jul 27, 11:39 pm EDT
Result
PTS
outside of trading hours
689.1
Jul 28, 12:39 pm JST
Summary Chart Historical News Financial Result
PER
PBR
38.5
Yield
ー%
Margin Trading Ratio
18.69
Stock Price
Jul 28, 2025
Opening Jul 28, 9:03 am
692 JPY 4.68 USD
Previous Close Jul 25
678 JPY 4.61 USD
High Jul 28, 11:24 am
701 JPY 4.74 USD
Low Jul 28, 9:28 am
676 JPY 4.57 USD
Volume
5,332,500
Trading Value
3.67B JPY 0.02B USD
VWAP
687.69 JPY 4.66 USD
Minimum Trading Value
68,800 JPY 467 USD
Market Cap
0.08T JPY 0.51B USD
Number of Trades
3,220
Liquidity & Number of Trades
As of Jul 28, 2025
Liquidity
High
1-Year Average
2,340
1-Year High Jul 17, 2025
31,879
Margin Trading
Date Short Interest Long Margin Positions Ratio
Jul 18, 2025 4,114,200 14,941,400 3.63
Jul 11, 2025 2,889,800 13,689,300 4.74
Jul 4, 2025 2,660,000 13,274,500 4.99
Jun 27, 2025 2,824,200 13,640,900 4.83
Jun 20, 2025 2,861,600 13,267,600 4.64
Company Profile
HEALIOS K.K. develops treatments for intractable diseases using iPS cells. The company collaborates with Sumitomo Pharma and has a business alliance with Nikon.
Sector
Pharmaceuticals
HEALIOS K.K. conducts research and development of regenerative medicine products utilizing iPS cell technology. In the field of somatic stem cell regenerative medicine, the company is advancing the development of HLCM051 for acute cerebral infarction and ARDS (Acute Respiratory Distress Syndrome). In the iPSC regenerative medicine field, which involves transplanting cells with functions similar to the human body created by differentiating iPS cells, HEALIOS K.K. is developing a next-generation platform to create Universal Donor Cells (UDC) with reduced risk of immune rejection. The company's pipeline includes research and development in cancer immunotherapy, age-related macular degeneration treatment, and liver disease treatment. Through joint development with Sumitomo Pharma and collaborations with domestic and international research institutions, HEALIOS K.K. aims to realize new treatments for intractable diseases.